HLX43 

HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research^[1][2].

HLX43 is stable in the plasma of rats and cynomolgus monkeys^[2].
HLX43 induces tumor regression in multiple PD-L1+ CDX and PDX models, and was well tolerated across all dosing groups^[2].
HLX43 (8 mg/kg, three times for a week) significantly reduces tumors in the MDA-MB-231 model without causing weight loss^[2].
HLX43 shows well tolerability in rats and cynomolgus monkeys, with the maximum tolerated dose being 60 mg/kg in rats and 10 mg/kg in non-human primates^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

153714 (average)

Liquid

Colorless to light yellow

[HLX43]

Shipping with dry ice.

-80°C, protect from light

• [1]. Wang J, et al. A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors. 2025.

  [2]. Shan, Y. et al. 693P Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models. Annals of Oncology, Volume 34, S483